HME as a transformative platform in pharmaceutics: from molecular dispersion engineering to personalized drug delivery

Hot melt extrusion (HME) has become a major continuous manufacturing approach for producing amorphous solid dispersions (ASDs) that address the poor solubility and limited bioavailability of many contemporary drug candidates. Through controlled application of heat and mechanical shear, HME enables uniform molecular dispersion of the drug within a polymer carrier, converting crystalline APIs into kinetically stable amorphous systems with improved dissolution profiles and enhanced supersaturation. The performance of these extrudates is determined by essential Critical Quality Attributes (CQAs) such as glass transition temperature (Tg), residual crystallinity, dissolution behaviour and impurity levels which in turn depend on Critical Material Attributes (CMAs) including polymer properties, drug loading, hygroscopicity and particle size, as well as Critical Process Parameters (CPPs) like screw speed, barrel temperature, residence time and specific mechanical energy (SME).

A Quality by Design (QbD) framework provides a structured basis for formulation and process optimization by mapping the relationships between CQAs, CMAs and CPPs to establish a robust design space. Modern implementation strategies increasingly incorporate Process Analytical Technology (PAT) tools and real–time release testing (RTRT), allowing continuous monitoring of amorphization, mixing efficiency and chemical stability in alignment with FDA, EMA, and ICH regulatory expectations. Emerging case studies highlight the broad applicability of HME beyond traditional bioavailability enhancement, with successful use in taste–masked paediatric formulations, abuse–deterrent platforms, fixed–dose combinations (FDCs), and gastro–retentive systems. Together, these developments reinforce HME as a mature, solvent–free, and industrially scalable technology for manufacturing advanced oral drug products with consistently high performance and improved patient outcomes.